Mobile Menu Mobile Close

Search

LEARN MORE ABOUT OUR FEARLESS PURSUIT

LATEST NEWS

TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from an integrated safety analysis of UKONIQ ®  (umbralisib), the Company’s inhibitor of PI3k-delta and CK1-epsilon, in patients with relapsed or refractory lymphoid

Read More >

GET INVESTOR
INFORMATION

HEAR OUR
STORY

READ OUR
PUBLICATIONS

EXPLORE OUR
PIPELINE

JOIN OUR
TEAM

HEAR OUR
STORY

EXPLORE OUR
PIPELINE

READ OUR
PUBLICATIONS

JOIN OUR
TEAM

GET INVESTOR
INFORMATION

LATEST NEWS

TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from an integrated safety analysis of UKONIQ ®  (umbralisib), the Company’s inhibitor of PI3k-delta and CK1-epsilon, in patients with relapsed or refractory lymphoid

Read More >
logo

Email Us 1-877-575-TGTX (8489)

©2021 TG Therapeutics, Inc. All rights reserved.

You are now leaving TGTherapeutics.com, a website wholly owned and operated by TG Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. TG Therapeutics, Inc., does not endorse or influence the content of websites that are not owned or operated by TG Therapeutics, Inc.

CONTINUE Return to tgtherapeutics.com